Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
The use of mouse models has been an invaluable resource in cancer research but their generation is lengthy and costly. Here the authors describe an approach to generate engineered mouse models carrying specific gene fusions and, as a proof of principle, show that Bcan-Ntrk1 fusion leads to glioblast...
Guardado en:
Autores principales: | Peter J. Cook, Rozario Thomas, Ram Kannan, Esther Sanchez de Leon, Alexander Drilon, Marc K. Rosenblum, Maurizio Scaltriti, Robert Benezra, Andrea Ventura |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ddd7582963914757848181c6d8b5e60f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correction: Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
por: Peter J. Cook, et al.
Publicado: (2018) -
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Christopher Alvarez-Breckenridge, et al.
Publicado: (2017) -
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
por: Ana S. Guerreiro Stucklin, et al.
Publicado: (2019) -
A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways
por: Siobhan S. Pattwell, et al.
Publicado: (2020) -
NTRK fusion in Japanese colorectal adenocarcinomas
por: Yuya Yamashiro, et al.
Publicado: (2021)